Molecular Partners AG reported its unaudited financial results for the third quarter of 2025, showing cash and cash equivalents of CHF 105 million as of September 30, 2025. The company forecast total operating expenses for 2025 at CHF 55–60 million, including approximately CHF 6 million in non‑cash costs such as share‑based payments and depreciation, and projected a cash runway extending through 2028.
In comparison, the company’s Q3 2024 results included revenue of CHF 0.681 million and a net loss of CHF 16.4 million. Full‑year 2024 operating expenses totaled CHF 66.2 million, indicating a reduction in operating‑expense guidance for 2025 driven by workforce efficiencies announced in June 2025.
The company’s guidance for 2025 reflects a focus on cost control and strategic investment. Operating‑expense guidance of CHF 55–60 million, with CHF 6 million in non‑cash items, is supported by the cash runway extension to 2028, achieved through operational efficiencies and a workforce reduction earlier in the year.
Clinically, the company advanced its lead Radio‑DARPin MP0712, filing an IND for a DLL3‑targeted therapy and expecting a Phase 1 start before year‑end 2025. Updated safety and efficacy data for MP0533 in acute myeloid leukemia were presented at the ASH meeting in December 2025. The partnership with Orano Med was expanded to support up to ten radiotherapy programs, leveraging 212Pb production expertise and the company’s DARPin platform.
Molecular Partners remains a pioneer in DARPin therapeutics, a novel class of protein drugs. While the company’s profitability remains negative, its financial position and pipeline progress provide a foundation for future product development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.